Loading
A phase 1/2 trial of TNG462, Zoldonrasib, Daraxonrasib in pancreatic ductal adenocarcinoma, run by Tango Therapeutics, Inc., now recruiting.
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients is a phase 1/2 interventional study registered as NCT06922591 by Tango Therapeutics, Inc., with 183 participants planned, started 2025-05-31 and due to reach its primary completion in 2027-06. Interventions recorded: TNG462, RMC-9805, RMC-6236, mFOLFIRINOX, gemcitabine/nab-paclitaxel. Conditions listed: PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC, RAS Mutation. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Zoldonrasib, Daraxonrasib, Paclitaxel / nab-paclitaxel, Gemcitabine.
Shares TNG462, Tango Therapeutics.
Shares TNG462, Tango Therapeutics.
Shares Zoldonrasib, Daraxonrasib, Paclitaxel / nab-paclitaxel, Gemcitabine.
Shares FOLFIRINOX / mFOLFIRINOX, Paclitaxel / nab-paclitaxel, Gemcitabine, Pancreatic ductal adenocarcinoma.
Shares Zoldonrasib, Daraxonrasib, Pancreatic ductal adenocarcinoma.
Shares Zoldonrasib, Daraxonrasib, Pancreatic ductal adenocarcinoma.
Shares FOLFIRINOX / mFOLFIRINOX, Gemcitabine, Pancreatic ductal adenocarcinoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/